首页> 外文期刊>Pulse. >Renal Sympathetic Denervation in Patients with Resistant Hypertension: A Feasibility Study
【24h】

Renal Sympathetic Denervation in Patients with Resistant Hypertension: A Feasibility Study

机译:抗性高血压患者的肾交感神经视障:可行性研究

获取原文
获取原文并翻译 | 示例
           

摘要

Background/Aims: We assessed the feasibility of renal sympathetic denervation (RDN) treatment in patients with resistant hypertension using the Iberis? RDN system. This study was a prospective, multicenter, single-arm feasibility registry. Methods: We collected data from patients who underwent RDN treatment using the Iberis system. From November 2014 to February 2016, 16 patients from 6 centers in Europe were enrolled in this registry. Results: Consistent reductions in the 24-h systolic blood pressure (SBP) and diastolic blood pressure were obtained. At any follow-up point, more than 70% of the patients were responders. The change in the 24-h SBP at 1 month was strongly correlated with that at 12 months. Conclusion: The Iberis system is safe and effective in patients for the treatment of resistant hypertension. Furthermore, our results suggest that we can estimate the effect of RDN in the long term at the 1-month follow-up point using the 24-h SBP.
机译:背景/目的:我们评估了使用Iberis抗性高血压患者肾交感神经去除(RDN)治疗的可行性吗? RDN系统。 本研究是一项潜在的多中心单臂可行性注册表。 方法:我们使用Iberis系统从接受RDN治疗的患者中收集数据。 从2014年11月到2016年2月,欧洲6名中心的16名患者注册了这一登记处。 结果:获得24-H收缩压(SBP)和舒张压的一致减少。 在任何后续观点,超过70%的患者都是响应者。 1个月的24-H SBP的变化与12个月相比强烈相关。 结论:Iberis系统在治疗抗性高血压患者中是安全有效的。 此外,我们的结果表明,我们可以使用24-H SBP在1个月随访时间估计RDN的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号